Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

Abstract

Dasatinib (BMS-354825), a novel dual SRC/BCR-ABL kinase inhibitor, exhibits greater potency than imatinib mesylate (IM) and inhibits the majority of kinase mutations in IM-resistant chronic myeloid leukemia (CML). We have previously demonstrated that IM reversibly blocks proliferation but does not induce apoptosis of primitive CML cells. Here, we have… (More)

Topics

5 Figures and Tables

Cite this paper

@article{Copland2006DasatinibT, title={Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.}, author={Mhairi Copland and Ashley M Hamilton and Lucy J Elrick and Janet W Baird and Elaine K. Allan and Niove E. Jordanides and Martin Barow and Joanne C Mountford and Tessa L Holyoake}, journal={Blood}, year={2006}, volume={107 11}, pages={4532-9} }